NASDAQ$KIDS
OrthoPediatrics Corp · Q3 2023 earnings
Q3 2023 earnings · · Investor relations
Briefing
OrthoPediatrics' Q3 2023 financial performance demonstrated strong revenue growth and increased profitability.
OrthoPediatrics Corp. reported record-setting quarterly revenue of $40.0 million for Q3 2023, a 14% increase compared to the same period last year. The company also achieved record Adjusted EBITDA of $3.6 million. They reiterated full year 2023 revenue guidance of $148.0 million to $151.0 million and raised adjusted EBITDA guidance to $4.0 million to $5.0 million for the full year of 2023.
- Total revenue reached $40.0 million, up 14% from Q3 2022, with domestic revenue increasing by 11% and international revenue by 26%.
- Trauma & Deformity revenue grew by 21%, while Scoliosis revenue increased by 3%; Sports Medicine/Other revenue decreased by 20%.
- Adjusted EBITDA reached a record $3.6 million, compared to $1.9 million in Q3 2022.
- The company launched the Pediatric Nailing Platform TIBIA system and the DF2® Brace, expanding its product offerings.
Headline financials
Revenue & EPS history
OrthoPediatrics · Revenue · Quarterly
$40M
Revenue by segment
OrthoPediatrics · $40M total across 3 segments · Q3 2023
- Trauma and Deformity$28.8M+20.5%72.1%
- Scoliosis$10.3M+3.3%25.8%
- Sports Medicine/Other$862K-20.1%2.2%
Forward guidance
The Company reiterated its revenue guidance to be in the range of $148.0 million to $151.0 million, representing growth of 21% to 23% over 2022 revenue. The Company now expects annual set deployments of approximately $23.0 million and $4.0 million to $5.0 million of adjusted EBITDA for the full year of 2023.
Tailwinds
- Revenue guidance of $148.0 million to $151.0 million, representing growth of 21% to 23% over 2022 revenue.
- Adjusted EBITDA guidance of $4.0 million to $5.0 million for the full year of 2023.
- Expecting annual set deployments of approximately $23.0 million.
- Strong balance sheet.
- Recent product portfolio expansion.
Headwinds
- Not enough information to provide negative guidance
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q3 2023
-0.6%
Avg return
Earnings day
-1.0%
Avg return
5 days after
-0.4%
Avg return
30 days after
50%
17 / 34 earnings
Positive
+13.1%
Q2 2022
Best reaction
-13.0%
Q3 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +3.8% | +13.7% | +14.0% | |
| Q4 2025 | +8.3% | +3.9% | -12.8% | |
| Q3 2025 | -2.6% | -3.0% | +9.3% | |
| Q1 2025 | +4.0% | +4.6% | -4.5% | |
| Q4 2024 | +11.9% | +7.0% | -0.8% | |
| Q3 2024 | -7.8% | -16.2% | -22.3% | |
| Q2 2024 | -7.8% | -9.0% | +3.8% | |
| Q1 2024 | +5.7% | -5.3% | -1.9% | |
| Q4 2023 | +5.4% | +1.9% | +0.8% | |
| Q3 2023 | +4.2% | -5.1% | +8.9% | |
| Q2 2023 | -4.6% | -4.9% | -7.2% | |
| Q1 2023 | -7.5% | -8.0% | -14.4% | |
| Q4 2022 | +0.5% | +1.7% | -0.8% | |
| Q3 2022 | -13.0% | -12.4% | +0.8% | |
| Q2 2022 | +13.1% | +19.2% | -0.8% | |
| Q1 2022 | -10.2% | -17.7% | -8.1% | |
| Q4 2021 | -5.8% | -6.3% | -2.0% | |
| Q3 2021 | +2.0% | +0.4% | -19.4% | |
| Q2 2021 | +6.9% | +4.5% | +9.2% | |
| Q1 2021 | +10.1% | +4.4% | +4.4% | |
| Q4 2020 | -7.1% | -8.6% | +2.3% | |
| Q3 2020 | -6.5% | +6.5% | -2.1% | |
| Q2 2020 | +4.7% | +9.7% | -0.6% | |
| Q1 2020 | +2.8% | +4.8% | +10.0% | |
| Q4 2019 | +1.1% | -4.5% | -19.5% | |
| Q3 2019 | +5.7% | +8.9% | +10.6% | |
| Q2 2019 | -0.2% | -1.0% | +10.9% | |
| Q1 2019 | -9.5% | -10.3% | -8.3% | |
| Q4 2018 | -4.3% | -2.0% | -6.2% | |
| Q3 2018 | -12.5% | -16.0% | -11.4% | |
| Q2 2018 | +2.7% | +2.7% | +23.7% | |
| Q1 2018 | -1.1% | +1.9% | +32.0% | |
| Q4 2017 | -1.9% | +3.4% | -2.9% | |
| Q3 2017 | -11.3% | -2.0% | -8.5% | |
| Q1 2017 | — | — | — | |
| Q4 2016 | — | — | — | |
| Q3 2016 | — | — | — | |
| Q2 2016 | — | — | — | |
| Q1 2016 | — | — | — | |
| Q1 2015 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro